 |
| In this handout photo released by the University of Oxford a doctor takes blood samples for use in a coronavirus vaccine trial in Oxford, England, Thursday June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday July 20, 2020 in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. (John Cairns, University of Oxford via AP) |
Early data from trials of three potential COVID-19 vaccines released on Monday, including a closely-watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight the novel coronavirus without serious side effects.
옥스포드 대학의 정밀 관찰 후보물질을 포함한 3가지 잠재적 코로나19 백신에 대한 임상시험에서 나온 초기 데이터가 백신이 심각한 부작용 없이 신종 코로나바이러스를 인지하고 싸울 수 있도록 면역체계를 훈련시킬 수 있다는 확신을 높였다.
Whether any of these efforts will result in a vaccine capable of protecting billions of people and ending the global pandemic that has claimed more than 600,000 lives is still far from clear.
그러나 이러한 시도들 중 어느 것이 수십억명의 사람들을 보호할 수 있는 백신을 만들어내고, 60만명 이상의 생명을 앗아간 이 세계적인 전염병을 종식시킬 수 있을지는 아직 명확하지 않다.
All will require much larger studies to prove they can safely prevent infection or serious disease.
백신들은 모두 감염이나 심각한 질병을 안전하게 예방할 수 있다는 것을 증명하기 위해 훨씬 더 많은 연구가 필요할 것이다.
The vaccine being developed by British drugmaker AstraZeneca along with the Oxford University, induced an immune response in all study participants who received two doses without any worrisome side effects. (Reuters)
영국의 제약회사 아스트라제네카가 옥스포드대와 함께 개발 중인 이 백신은 우려스러운 부작용 없이 2회 투약을 받은 모든 임상 참가자들에게 면역 반응을 유도했다.
![[INTERVIEW] 'Korea, US can create synergy in space industry': NASA ambassador](https://img.koreatimes.co.kr/upload/thumbnailV2/97d561c153754ca19e3c626ec734eb82.jpg/dims/resize/178/optimize)
